GENETIC RESISTANCE TO HIV
Infection with human immunodeficiency virus-1 (HIV-1) remains a major cause of premature death worldwide. In order to enter and infect immune cells, HIV-1 binds to cell surface receptors including the CCR5 chemokine receptor (Fig. 1A) . A welldescribed functional polymorphism in the CCR5 gene comprises a 32-bp deletion (called CCR5-Á32) which results in a lack of the last three transmembrane domains of the CCR5 protein [1] . The mutated protein is contained in the cytoplasm, resulting in a complete lack of CCR5 cell surface receptor. In the absence of this co-receptor binding site, HIV-1 is unable to enter the cell (Fig. 1B) ; individuals homozygous for CCR5-Á32 display complete resistance to HIV-1, whereas heterozygotes have a delayed onset of AIDS [1] .
EVOLUTIONARY PERSPECTIVES
Chemokines and their receptors play a central role in the trafficking and activation of lymphocytes, but perhaps surprisingly there are no apparent pathological consequences of CCR5-Á32 homozygosity. Intriguingly, this variant displays marked population differentiation which would not be explained by the very recent emergence of HIV-1 in subSaharan Africa: the CCR5-Á32 allele is highly prevalent in Europeans (frequency up to 14%), while very rare or absent among African and Asian populations [2] .
Early studies suggested that the CCR5-Á32 allele arose relatively recently (700 years ago) and was subject to strong positive selection [2] . Infection with Yersinia pestis-the cause of the bubonic plague in Europe during this time period-or smallpox were suggested as potential selective factors favoring CCR5-Á32 [2]. HIV and smallpox both cause cellular immune dysfunction and both enter leukocytes using chemokine receptors. If exposure to smallpox provided selective pressure favoring CCR5-Á32, it is plausible that exposed populations now have an evolutionary advantage in facing HIV [3] . Recently, however, high-density genetic maps have questioned the evidence for a recent origin of CCR5-Á32, suggesting instead that this allele may have arisen 5000 years ago [4] , under neutral evolution, or subject to an ancient, currently unknown positive selective pressure. 
FUTURE IMPLICATIONS
Antagonism of CCR5 interferes with HIV-1 cell entry, and indeed the CCR5 antagonist drug maraviroc is approved by the FDA for treatment of exclusively CCR5-tropic viral strains of HIV-1 [5] . The clinical relevance of CCR5-Á32 is further illustrated by a case of long-term HIV control following stemcell transplantation from a CCR5-Á32 homozygous donor [6] , although viral escape through chemokine receptors other than CCR5 may limit the success of this approach [7] . Of broader relevance, development of a therapy that eliminates the transmembrane portion of the CCR5 protein to mimic the advantage conferred by the natural CCR5-Á32 variant might constitute a functional HIV-1 cure. A 'gene editing' approach using infusion of autologous CD4 T cells which have been modified by zinc finger nucleases to disrupt CCR5 (mimicking CCR5-Á32) appears safe and confers partial disease resistance [8] . This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
